Logo DaVita

DaVita (DVA) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
DaVita · Health Care · ref. ETF XLV · 50 calls · price $178.88
💬JPI AI AssistantTry it →
What the company does: DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.

📈 DaVita (DVA) stock price

$178.88+31.5% over range
Aug 28, 25low $103.87 · high $240.96Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
60% recommend buying · 5 analysts
📊 JPI status : DaVita has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 DVA price target & analyst consensusprice $179

The price target · all analysts combined (5 targets)
Highest target · 1 firm of 5$270+50.9%
Median target · of 5 targets$220+23.0%
Lowest target · 1 firm of 5$215+20.2%
Current price$178.88
Where these 5 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 5100% $215 ↔ $270
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS66% of its targets hit on this sector (355 calls tested). It aims for $270 (+51 %), call made on July 11, 2026, maturing on July 11, 2027 (48 d ago).

The 4 reliable analysts $222+24 %
The 1 other firm $220+23 %
How to read it: the 4 reliable firms are not filtered by optimism — 4 aim above the price, 0 below, hence their $222 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 5 ratings (last 6 months)
Strong Buy00%
Buy360%
Hold240%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about DaVita? The JPI assistant answers using our backtest data.

📈 DaVita fundamentals: valuation, margins & growth › open the full page

P/E 15.3Net margin 6.0 %Revenue growth +5.2 %Cheap for the growth

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 5 %
2023
Rev +5%Profit +23%
2024
Rev +6%Profit +35%
2025
Rev +6%Profit −20%

🔎 Detailed analyses

✅ Historical analyst reliability on DVA

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
Barclays  100% +36.7% 2
Keybanc  100% +20.8% 2
Deutsche Bank  75% +18.2% 8
UBS  71% +18.4% 7
Feltl & Co. 67% +18.6% 3
Goldman Sachs  67% +17.4% 3
B of A Securities  67% +3.1% 9
JP Morgan  67% -8.7% 3
Raymond James  50% +1.1% 4

📊 What $1,000 invested in DaVita would be worth › open the full page

In short — $1,000 invested in DaVita 10 years ago would be worth $3,192 today, i.e. +12%/yr on average. Best year: 2020 (+56%), worst: 2022 (-34%). Price performance, excluding dividends.

If I'd invested $1,000 in DaVita

InvestmentWorth todayGain
1 years ago$1,488+49%
3 years ago$2,980+198%
5 years ago$1,895+90%
→ See DaVita's full return history + gain calculator

Return by year (DaVita)

YearReturn$1,000 invested at year start
2026 (YTD)+96%$1,958 (+96%)
2025-24%$1,488 (+49%)
2024+43%$2,124 (+112%)
→ See DaVita's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on DaVita

Loading news…

📋 All analyst calls on DVA

TD Cowen 
Aug 7, 26
▲ Buy · 🎯$220
Price at call : $183.69 — upside +20%
Today : $178.88 — upside +23%
🎯 on DVA : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Aug 7, 27
■ Hold neutral · not a buy · 🎯$215
Price at call : $183.77 — gap to target +17%
Today : $178.88 — gap to target +20%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Aug 7, 27
Barclays 
Aug 5, 26
■ Equal-Weight neutral · not a buy · 🎯$224
Price at call : $188.69 — gap to target +19%
Today : $178.88 — gap to target +25%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Aug 5, 27
■ Hold neutral · not a buy · 🎯$250
Price at call : $232.41 — gap to target +8%
Today : $178.88 — gap to target +40%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 14, 27
UBS 
Jul 10, 26
▲ Buy · 🎯$270
Price at call : $235.58 — upside +15%
Today : $178.88 — upside +51%
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jul 10, 27
Barclays 
Jul 9, 26
■ Equal-Weight neutral · not a buy · 🎯$218
Price at call : $232.8 — gap to target -6%
Today : $178.88 — gap to target +22%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jul 9, 27
TD Cowen 
May 11, 26
■ Hold neutral · not a buy · 🎯$201
Price at call : $200.54 — gap to target +0%
Today : $178.88 — gap to target +12%
🎯 on DVA : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : May 11, 27
■ Hold neutral · not a buy · 🎯$205
Price at call : $198.93 — gap to target +3%
Today : $178.88 — gap to target +15%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : May 8, 27
See the other 42 calls, newest to oldest
Barclays 
May 8, 26
■ Equal-Weight neutral · not a buy · 🎯$194
Price at call : $198.93 — gap to target -2%
Today : $178.88 — gap to target +8%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : May 8, 27
UBS 
May 8, 26
▲ Buy · 🎯$235
Price at call : $198.65 — upside +18%
Today : $178.88 — upside +31%
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : May 8, 27
Deutsche Bank 
May 6, 26
▲ Buy · 🎯$220
Price at call : $193.88 — upside +13%
Today : $178.88 — upside +23%
🎯 on DVA : 100% (1 call matured) · 📊 on Health : 53.3% · +4.5% (291 calls)
in progress (365j)
matures : May 6, 27
UBS 
Feb 4, 26
▲ Buy · 🎯$190
Price at call : $149.22 — upside +27%
Today : $178.88 — upside +6%
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Feb 4, 27
Barclays 
Feb 3, 26
■ Equal-Weight neutral · not a buy · 🎯$158
Price at call : $134.73 — gap to target +17%
Today : $178.88 — gap to target -12%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 3, 27
TD Cowen 
Nov 3, 25
■ Hold neutral · not a buy · 🎯$133
Price at call : $119.97 — gap to target +11%
Today : $178.88 — gap to target -26%
🎯 on DVA : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Nov 3, 26
Barclays 
Oct 30, 25
■ Equal-Weight neutral · not a buy · 🎯$143
Price at call : $119.02 — gap to target +20%
Today : $178.88 — gap to target -20%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Oct 30, 26
Barclays 
Oct 9, 25
■ Equal-Weight neutral · not a buy · 🎯$149
Price at call : $126.38 — gap to target +18%
Today : $178.88 — gap to target -17%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Oct 9, 26
▼ Underperform · 🎯$140
Price at call : $133.24 — upside +5%
Today : $178.88 — upside -22%
🎯 on DVA : 50% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Sep 10, 26
Barclays 
Aug 7, 25
■ Equal-Weight neutral · not a buy · 🎯$160
Price at call : $127.69 — gap to target +25%
Today : $178.88 — gap to target -11%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Aug 7, 26
■ Hold neutral · not a buy · 🎯$164
Price at call : $144.96 — gap to target +13%
Today : $178.88 — gap to target -8%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : May 19, 26
Barclays 
Feb 18, 25
■ Equal-Weight neutral · not a buy · 🎯$169
Price at call : $155.05 — gap to target +9%
Today : $178.88 — gap to target -6%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 18, 26
Barclays 
Oct 31, 24
■ Equal-Weight neutral · not a buy · 🎯$164
Price at call : $141.59 — gap to target +16%
Today : $178.88 — gap to target -8%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Oct 31, 25
■ Hold neutral · not a buy · 🎯$175
Price at call : $157.54 — gap to target +11%
Today : $178.88 — gap to target -2%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Oct 7, 25
■ Hold neutral · not a buy · 🎯$165
Price at call : $150.6 — gap to target +10%
Today : $178.88 — gap to target -8%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Aug 20, 25
UBS 
Aug 8, 24
▲ Buy · 🎯$175
Price at call : $140.3 — upside +25%
Today : $178.88 — upside -2%
Expected +25% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
-8.0%
stock -8% · XLV -13%
matured Aug 8, 25
▼ Underperform · 🎯$145
Price at call : $138.88 — upside +4%
Today : $178.88 — upside -19%
Expected +4% · Actual -7% · Reason (≤ −15%) : ✗ No
🎯 on DVA : 50% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
+6.8%
stock -7% · XLV -13%
matured Aug 7, 25
TD Cowen 
Jul 24, 24
■ Hold neutral · not a buy · 🎯$150
Price at call : $142.5 — gap to target +5%
Today : $178.88 — gap to target -16%
🎯 on DVA : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Jul 24, 25
■ Hold neutral · not a buy · 🎯$150
Price at call : $136.48 — gap to target +10%
Today : $178.88 — gap to target -16%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : May 15, 25
Barclays 
May 6, 24
■ Equal-Weight neutral · not a buy · 🎯$150
Price at call : $137.69 — gap to target +9%
Today : $178.88 — gap to target -16%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : May 6, 25
Barclays 
Mar 6, 24
■ Equal-Weight neutral · not a buy · 🎯$133
Price at call : $134.08 — gap to target -1%
Today : $178.88 — gap to target -26%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Mar 6, 25
■ Hold neutral · not a buy · 🎯$135
Price at call : $123 — gap to target +10%
Today : $178.88 — gap to target -25%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Feb 19, 25
UBS 
Feb 15, 24
▲ Buy · 🎯$145
Price at call : $122.22 — upside +19%
Today : $178.88 — upside -19%
Expected +19% · Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+26.9%
stock +27% · XLV -1%
matured Feb 14, 25
UBS 
Feb 14, 24
▲ Buy · 🎯$134
Price at call : $119.87 — upside +12%
Today : $178.88 — upside -25%
Expected +12% · Actual +31% · Reason (≥ +15%) : ✓ Yes
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+31.3%
stock +31% · XLV -0%
matured Feb 13, 25
■ Hold neutral · not a buy · 🎯$130
Price at call : $123.41 — gap to target +5%
Today : $178.88 — gap to target -27%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Feb 13, 25
UBS 
Nov 17, 23
▲ Buy · 🎯$113
Price at call : $97.53 — upside +16%
Today : $178.88 — upside -37%
Expected +16% · Actual +61% · Reason (≥ +15%) : ✓ Yes
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+61.4%
stock +61% · XLV +10%
matured Nov 16, 24
■ Hold neutral · not a buy · 🎯$104
Price at call : $73.79 — gap to target +41%
Today : $178.88 — gap to target -42%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Oct 10, 24
UBS 
Aug 7, 23
▲ Buy · 🎯$142
Price at call : $112.68 — upside +26%
Today : $178.88 — upside -21%
Expected +26% · Actual +22% · Reason (≥ +15%) : ✓ Yes
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+21.6%
stock +22% · XLV +10%
matured Aug 6, 24
■ Hold neutral · not a buy · 🎯$115
Price at call : $103.74 — gap to target +11%
Today : $178.88 — gap to target -36%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 12, 24
Bernstein 
May 15, 23
■ Market Perform neutral · not a buy · 🎯$100
Price at call : $96.86 — gap to target +3%
Today : $178.88 — gap to target -44%
🎯 on DVA : no call matured yet · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : May 14, 24
Deutsche Bank 
May 9, 23
■ Hold neutral · not a buy · 🎯$113
Price at call : $99.27 — gap to target +14%
Today : $178.88 — gap to target -37%
🎯 on DVA : 100% (1 call matured) · 📊 on Health : 53.3% · +4.5% (291 calls)
in progress (365j)
matures : May 8, 24
■ Hold neutral · not a buy · 🎯$100
Price at call : $100.72 — gap to target -1%
Today : $178.88 — gap to target -44%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : May 8, 24
TD Cowen 
May 9, 23
■ Market Perform neutral · not a buy · 🎯$98
Price at call : $100.72 — gap to target -3%
Today : $178.88 — gap to target -45%
🎯 on DVA : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : May 8, 24
▼ Underperform · 🎯$96
Price at call : $100.72 — upside -5%
Today : $178.88 — upside -46%
Expected -5% · Actual +35% · Reason (≤ −15%) : ✗ No
🎯 on DVA : 50% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
-34.9%
stock +35% · XLV +7%
matured May 8, 24
Cowen & Co.
Feb 23, 23
▲ Outperform · 🎯$90
Price at call : $82.31 — upside +9%
Today : $178.88 — upside -50%
Expected +9% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on DVA : 100% (1 call matured) · 📊 unranked overall
+51.8%
stock +52% · XLV +14%
matured Feb 23, 24
■ Hold neutral · not a buy · 🎯$90
Price at call : $82.87 — gap to target +9%
Today : $178.88 — gap to target -50%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Feb 23, 24
■ Hold neutral · not a buy · 🎯$75
Price at call : $69.87 — gap to target +7%
Today : $178.88 — gap to target -58%
🎯 on DVA : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Oct 31, 23
Barclays 
Oct 31, 22
■ Equal-Weight neutral · not a buy · 🎯$81
Price at call : $73.01 — gap to target +11%
Today : $178.88 — gap to target -55%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Oct 31, 23
UBS 
Oct 31, 22
■ Neutral neutral · not a buy · 🎯$74
Price at call : $73.01 — gap to target +1%
Today : $178.88 — gap to target -59%
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Oct 31, 23
UBS 
Aug 19, 22
▲ Buy · 🎯$117
Price at call : $93.21 — upside +26%
Today : $178.88 — upside -35%
Expected +26% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on DVA : 83% (6 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+9.3%
stock +9% · XLV +1%
matured Aug 19, 23
Barclays 
Aug 4, 22
■ Equal-Weight neutral · not a buy · 🎯$103
Price at call : $85.31 — gap to target +21%
Today : $178.88 — gap to target -42%
🎯 on DVA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Aug 4, 23
Deutsche Bank 
Aug 2, 22
▲ Buy · 🎯$97
Price at call : $84.8 — upside +14%
Today : $178.88 — upside -46%
Expected +14% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on DVA : 100% (1 call matured) · 📊 on Health : 53.3% · +4.5% (291 calls)
+19.8%
stock +20% · XLV +1%
matured Aug 2, 23

Frequently asked questions

Should I buy DaVita stock?

This isn't buy advice. For DaVita, the analyst consensus is "Buy", with an average price target of $220 (+23% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on DaVita). We show the numbers — you decide.

Is it too late to buy DaVita? How high can it go?

The most bullish analyst target on DaVita is $270 (+51% above today's price); the average is $220. That's the upside they see. Check how reliable those analysts have actually been on DaVita on our site before trusting it.

Is DaVita still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 9 analysts have a real record on DaVita, the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in DaVita? The case for and against

The arguments for and against, one by one, from the numbers: why invest in DVA (and why hesitate).

What has DaVita's past performance been?

Historical returns and a "how much if I had invested" calculator: DVA performance & returns.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)